Publications

Rajan A, Pan Y, Mahtani P, Niec R, Longman R, Gerber J, Lukin D, Scherl E, Battat R. The Impact of Confounders on Symptom-Endoscopic Discordances in Crohn's Disease. Crohns Colitis 360. 2023;5(2):otad017.

Smith ES, Chen J, Pan Y, Mahtani P, Lukin D, Ahmed W, Longman R, Burakoff R, Scherl E, Battat R. The Relationship Between the Endoscopic Healing Index, Fecal Calprotectin, and Magnetic Resonance Enterography in Crohn's Disease. J Clin Gastroenterol. 2023;.

Chen K, Chen J, Smith E, Mathani P, Longman R, Lukin D, Scherl E, Gerber J, Battat R. Serum Ustekinumab Concentrations Are Associated With Improved Outcomes With the Magnetic Resonance Index of Activity for Crohn's Disease. Inflamm Bowel Dis. 2022;.

Pan Y, Ahmed W, Mahtani P, Wong R, Longman R, Lukin DJeremy, Scherl EJ, Battat R. Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease. Inflamm Bowel Dis. 2022;28(12):1865-1871.

Kumar A, Lukin D, Battat R, Schwartzman M, Mandl LA, Scherl E, Longman RS. Defining the phenotype, pathogenesis and treatment of Crohn's disease associated spondyloarthritis. J Gastroenterol. 2020;55(7):667-678.